Arcturus Therapeutics Holdings (ARCT) Common Equity (2018 - 2026)

Arcturus Therapeutics Holdings' Common Equity history runs 9 years deep, the most recent figure standing at $191.4 million for Q1 2026.

• Quarterly Common Equity fell 18.14% year-over-year to $191.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $191.4 million (down 18.14% YoY) and the FY2025 annual result came in at $214.0 million, down 11.2% from the prior year.
• Common Equity was $191.4 million for Q1 2026 at Arcturus Therapeutics Holdings, down from $214.0 million in the prior quarter.
• Across five years, Common Equity topped out at $329.2 million in Q1 2023 and bottomed at $145.7 million in Q3 2022.
• A 5-year average of $239.1 million and a median of $241.0 million in 2024 frame the typical range for Common Equity.
• Annual changes were most pronounced in 2022 — Common Equity slumped 47.6% — and 2023, when it soared 92.26%.
• Arcturus Therapeutics Holdings' Common Equity stood at $270.3 million in 2022, then rose by 3.03% to $278.5 million in 2023, then decreased by 13.48% to $241.0 million in 2024, then decreased by 11.2% to $214.0 million in 2025, then retreated by 10.57% to $191.4 million in 2026.
• Business Quant data shows ARCT's Common Equity at $191.4 million in Q1 2026, $214.0 million in Q4 2025, and $224.6 million in Q3 2025.